# Biotech Boom: Futures Flop as Oil Drops!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-04-13T14:00:00.268Z
Source: https://newsyai.com/edition/eb75224e-8ffd-43d0-8a19-32cd1ecfa507
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

# Biotech Boner Breaker: Futures Fart as Oil Fizzles!

**Premarket prick-tease**—**Dow futures limp at 47,634 -1.03%**[[1]](https://markets.businessinsider.com/premarket), **S&P 6,808 -0.69%**[[1]](https://markets.businessinsider.com/premarket), **Nasdaq 100 25,094 -0.74%**[[1]](https://markets.businessinsider.com/premarket); **WTI crude cockblocks at $96.57 -1.33%** post-Iran de-escalation dick-down—microcap maniacs mooning anyway with biotech blasts & penny pumps! [[1]](https://markets.businessinsider.com/premarket)[[2]](https://stockanalysis.com/markets/premarket/gainers/) **RMSG** messenger madness +101%, **VRAX** virus vroom +74%, **REPL** repli-rupture -63%—degens dick-measuring in the dawn dump! [[3]](https://www.benzinga.com/premarket)

---

## 1) Real Messenger (RMSG): “Low-Float Lube Job” vs “Rumor Rectum Reamer”

**Why it’s loud**  
**RMSG** exploding **+101% to $0.94** premarket nuke—**4.78M vol tsunami** drowning Nasdaq in degen diarrhea, topping gainers on zero-news zero-gravity pump! [[3]](https://www.benzinga.com/premarket)[[4]](https://www.tradingview.com/symbols/NASDAQ-RMSG)

**Bull case (messaging moonshot masturbation)**  
Low float fuck-fest + retail reddit rimjobs = squeeze to $2+; vague AI messenger pivot in comms boom, technical titty-twist from $0.43 lows—cum on the momentum! [[5]](https://robinhood.com/us/en/stocks/RMSG)[[3]](https://www.benzinga.com/premarket)

**Bear case (ghost stock gonorrhea)**  
No catalyst cock-suck, serial spunk with rev black hole & dilution dick-pic history—thin vol trap before rug-pull rim-wipe to pennies! [[6]](https://www.stocktitan.net/overview/RMSG)[[7]](https://finance.yahoo.com/quote/RMSG)

**My take, first principles (comms cum vs catalyst castration)**  
Core: Digital messaging rides AI chat wave but opacity overload screams pump-dump prostate probe. Oil irrelevant. **Grab $0.70-0.95**, **$1.20/$1.50 calls** squeeze spurt—**puts $0.60** fade fart. Risk: Newsless nut-shot.[[3]](https://www.benzinga.com/premarket)

---

## 2) Virax Biolabs (VRAX): “Virus Viagra Victory” vs “Retail Rug-Pull Rectal”

**Why it’s loud**  
**VRAX** viraling **+74% to $0.18** premarket virus vomit—**7.46M vol frenzy**, biotech boner from Mpox supplier whispers & retail reddit rampage! [[3]](https://www.benzinga.com/premarket)[[8]](https://stockanalysis.com/stocks/vrax)

**Bull case (biotech bug-buster bliss)**  
Mpox partnership pop + viral diagnostics demand in outbreak orgy—low float liquidity lube to $0.50+, HC Wainwright PT $1-$3 screams squeeze shaft! [[8]](https://stockanalysis.com/stocks/vrax)[[9]](https://markets.businessinsider.com/news/virax_biolabs_group_1-stock)

**Bear case (sentiment STD scam)**  
Retail-driven liquidity trap, no rev rigor + cash burn cockroach—35% spikes fade to flush, dilution deluge incoming! [[10]](https://www.ainvest.com/news/vrax-viral-sentiment-pop-retail-driven-liquidity-trap-unfolding-real-time-2604)[[11]](https://www.bitget.com/amp/news/detail/12560605357386)

**My take, first principles (pathogen profit vs penny plague)**  
Basics: Immunology IP moat in infectious frenzy but trial tease thin. Oil snooze. **Dip $0.12-0.20**, **$0.30/$0.50 calls** outbreak orgasm—**puts $0.10** hype herpes. Risk: Data dump dickslap.[[3]](https://www.benzinga.com/premarket)

---

## 3) Replimune (REPL): “Pipeline Prostate Pump” vs “FDA Fuck-Fest Flop”

**Why it’s loud**  
**REPL** imploding **-63% to $1.74** premarket apocalypse—**1.85M vol bloodbath** after FDA rejects RP1 skin cancer nod *again*, layoffs loom like last rites! [[3]](https://www.benzinga.com/premarket)[[12]](https://seekingalpha.com/news/4574207-replimune-sees-layoffs-fda-snubs-cancer-drug)

**Bull case (onco-orgy outlier)**  
Second CRL? Bullshit—pipeline persistence + $8.75 analyst circle-jerk means dip-buy to $10 on melanoma moat & combo trial cumshots! [[13]](https://www.marketbeat.com/stocks/NASDAQ/REPL)[[14]](https://www.marketwatch.com/investing/stock/repl)

**Bear case (regulatory rim-rape ruin)**  
FDA double-dickdown on RP1 + layoffs = death spiral, cash inferno & trial trash—bankruptcy ball-sack squeeze ahead! [[12]](https://seekingalpha.com/news/4574207-replimune-sees-layoffs-fda-snubs-cancer-drug)[[15]](https://finance.yahoo.com/quote/REPL/news)

**My take, first principles (virotherapy valor vs validation void)**  
Fundamentals: Oncolytic virus edge in IO wars but FDA flop flags execution erectile dysfunction. Oil irrelevant. **Blood $1.50-2.20**, **$3/$4 calls** rebound rod—**puts $1.20** layoff laxative. Risk: CRL cremation.[[3]](https://www.benzinga.com/premarket)

---

## Tape-Side Tactics (Biotech Bleed or Penny Prick Party?)

- **RMSG**: **$0.70-0.95** messenger meat; **$1.20C/$1.50C** squeeze squirt, **P$0.60** rug recoil.[[3]](https://www.benzinga.com/premarket)  
- **VRAX**: **$0.12-0.20** virus vein; **$0.30C/$0.50C** outbreak ooze, **P$0.10** trap turd.[[3]](https://www.benzinga.com/premarket)  
- **REPL**: **$1.50-2.20** repli-rim; **$3C/$4C** pipeline pop, **P$1.20** FDA flush.[[3]](https://www.benzinga.com/premarket)  

Futures flop or degen delight? Pound the pumps, bitch the bleeds—oil's limp, but micros maniac! DYOR, no fin advice, just filthy flips!
